Could a pill and light combo beat vitiligo?

NCT ID NCT07152626

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking a daily pill (ritlecitinib) plus twice-weekly narrowband UVB light therapy works better than the pill alone for vitiligo. About 56 adults with non-segmental vitiligo covering 4-60% of their body will take part. The main goal is to see how much skin color returns on the face and body after 52 weeks of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ritlecitinib (a JAK inhibitor pill) and narrowband UVB light therapy
What this could lead to: If this combination works better than the pill alone, it could offer a more effective treatment option for vitiligo, helping to restore skin color more quickly.
What could go wrong: This is a Phase 2 trial with only 56 participants, so results are still early. The added benefit of UVB may be small, and UVB requires frequent clinic visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VITILIGO

Contacts and locations

Locations

APHP
RECRUITING

Paris, Creteil, 94010, France
CHU La Réunion
RECRUITING

La Réunion, France
CHU de Bordeaux
RECRUITING

Bordeaux, 33000, France
CHu de Nice, Hôpital Archet
RECRUITING

Nice, Alpes-Maritime, 06200, France
HCL
RECRUITING

Lyon, 69000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.